Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 15 Life Science VC (Venture Capital) Funds in Italy in July 2025

Last updated: Jul 2025 A list of 15 VC (Venture Capital) funds that invest in Life science startups based in Italy. We rank investors based on the number of investments they made in Life science companies from Italy. We update this investor list every month.

Top 15 Life Science VC (Venture Capital) Funds in Italy in July 2025

Investor	Life Science Italy investments
Sofinnova Partners	4
Principia SGR	2
Indaco Venture Partners	2
Club degli Investitori	1
Roche Venture Fund	1
LIFTT	1
Sparta Capital	1
Claris Ventures	1
Italian Angels for Growth	1
CDP Venture Capital	1
Gaiae International	1
MCF Holding	1
Deep Blue Ventures	1
ReItaly21	1
JDRF T1D Fund	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

SafeHeal — SafeHeal is a clinical stage medical device manufacturer focusing on the development of anastomosis protection devices, including Colovac, for colorectal surgery.
Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.

Principia is an Italian Venture Capital firm with over Eur 80M under management. Currently Principia has two funds investing in digital start ups and expansion capital opportunities and in particular cases, we invest also in seed opportunities.

Investment focus

Health Care, Biotechnology, Software
Funding Round, Series A, Seed
Italy, United States, United Kingdom

Portfolio highlights

KLISBio — KLISBio is a medtech company currently developing a variety of regenerative medicine implantable products leveraging the power of silk fibroin to promote an endogenous repair of human soft tissues.
ENTEROME — We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
WISE — WISE (Wiringless Implantable Stretchable Electronics) is a start-up company created in 2011 with the mission of producing the new generation of leads for neuromodulation for treatment of chronic pain and Parkinson: unbreakable, less invasive and cheaper.

VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Italy, Switzerland, United States

Portfolio highlights

TES Pharma —
Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.
Valo Therapeutics — Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenovirusesinto targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer.

Club degli Investitori (Investors Club) is a network of investors and business angels that invest on early-stage SMEs and startups. The community of 300+ Members (entrepreneurs, CEOs, executive managers) actively scouts for investing opportunities on SMEs & startups and invests with a minimum ticket of €200k. The Club supports business byinvesting capital and by leveraging the Members' network and experience.Club degli Investitori is supported by Unicredit and KPMG Italy.

Investment focus

Health Care, E-Commerce, Information Technology
Seed, Series A, Series B
Italy, Switzerland, United Kingdom

Portfolio highlights

Ephos — Designing and manufacturing glass-based integrated photonic circuits that power the most advanced classical and quantum devices
Stema — It serves as a platform for hiring engineers
Lymphatica Medtech — Lymphatica Medtech is a medical device development company developing a minimally invasive solution for chronic lymphedema.Lymphedema is the chronic swelling that generally occurs in the arms or the legs.Lymphedema is most commonly caused by the removal of or the damage to the lymph nodes as a part of cancer treatment. It results from ablockage in the lymphatic system, which is part of the immune system. The blockage prevents the lymphatic system from draining excess fluids, and the fluid buildup leads to swelling, infections, and pain.Unfortunately, there is no cure for lymphedema. It can be managed with early diagnosis and diligent care of the affected limb, through daily compression, bandages, and manual drainage sessions. From the moment of the diagnosis, the life of lymphedema patients changes forever.Cancer and cancer-related interventions (i.e. surgery, radiotherapy) are frequent causes of lymphedema occurring both in the upper and lower limbs. Breast cancer survivors are at high risk for developing lymphedema, as well as patients treated for melanoma, pelvic and head and neck cancer or other cancer treatments that require lymph node dissection. Physical trauma can also result in lymphedema, a major cause of lymphatic disease among wounded veterans.Lymphedema is associated with significantly impaired quality of life, skin changes, increased risk of infection and in rare cases lymphedema itself may undergo malignant transformation.Lymphatica offers a permanent solution that will allow patients to regain their normal lifestyle.

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

A not-only-profit operating investment company, eager to create a bridge between innovative ideas, territory and capital.

Investment focus

Biotechnology, Software, Information Technology
Seed, Series A, Funding Round
Italy, United Kingdom, France

Portfolio highlights

Lumai — Lumai delivers fully optical computing for a quicker, smarter and more sustainable world. Lumai power the revolution of fully optical computing by working at the nexus of photonics and machine learning.
QSensAto — QSensAto is a quantum sensing company specializing in the development and research of integrated vapor cells and quantum atomic sensors.
Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.

Sparta Capital Ltd. focuses on product development, manufacturing, distribution, sales and service across a range of technologies. The Company's offering includes four different market verticals: transportation, mining, construction and energy (through biomass conversion). These offerings include optimization of energy consumption in thecommercial and manufacturing sectors, construction and energy through biomass conversion, energy conservation in mining, and energy savings in transportation. It is focused on the expansion of a range of divisions, including photoluminescent safety products division, energy audit (EMD) division, biomass division and mining division.

Investment focus

Solar, Life Science, Biotechnology
Series A, Series B
Italy, Germany

Portfolio highlights

Sunvigo — Sunvigo provides you with cheap solar power from your roof and real green power from the grid.
GFBiochemicals — GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass.In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for thisrevolution in chemicals and biofuels.GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.

Claris Ventures is a venture capital firm supporting the best scientists in building successful life sciences companies that will impact people's lives

Investment focus

Biotechnology, Health Care, Therapeutics
Seed, Series A, Series B
Italy, United Kingdom

Portfolio highlights

NeoPhore — NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
ALKemist Bio — ALKemist Bio is a biotech startup developing next-generation T cell therapies that target ALK-positive cancers. By reprogramming the immune system, the company aims to overcome resistance and deliver more effective, lasting treatments for solid tumors.
Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.

IAG is an angel investor network that offers access to its affiliates to early-stage venture opportunities. Its members to date have deployed over 22 million Euros to support 41 startups in the series seed/series A stage in many verticals, among which: Medtech, SAAS, e-commerce, Fintech, and high tech at large. Every investment opportunityat IAG is vetted by a professional team together with expert members of the group. Once invested, the company receives the support of up to two Investment champions, who bring their expertise to the table and help them succeed.

Investment focus

Software, E-Commerce, Health Care
Seed, Angel, Series A
Italy, United States, United Kingdom

Portfolio highlights

ALKemist Bio — ALKemist Bio provides cell treatment to cancer patients.
Rubedo Life Sciences — Rubedo Life Sciences is the Premier Longevity Company. Rubedo discovers and develops medicines to keep you biologically young.
Restorative Neurotechnologies — Siamo un'azienda di dispositivi medicali certificati per la riabilitazione cognitiva ed il trattamento di disturbi cognitivi post ictus.

CDP Venture Capital Sgr - National Innovation Fund aims to make venture capital a cornerstone of the country's economic development and innovation, creating the conditions for an overall and sustainable growth of the venture capital ecosystem.

Investment focus

Software, Information Technology, Health Care
Seed, Series A, Funding Round
Italy, United States, United Kingdom

Portfolio highlights

PhotonPath — Enabling seamless integration between Photonics and Electronics for a faster, more connected and sustainable future
Tulum Energy — Tulum Energy is a cutting-edge energy business developing a unique methane pyrolysis approach for low-cost, scalable clean hydrogen production that does not require CCS infrastructure.
Multiverse Computing — World leaders in quantum computing for the financial industry. The first quantum & quantum-inspired toolbox for finance.

Gaiae International is a leading importer and exporter of fruits and vegetables.

Investment focus

Biopharma, Life Science, Biotechnology
Funding Round
Italy

Portfolio highlights

Genoa Instruments — Genoa Instruments is an innovative startup dedicated to transforming the field of biomedical and health research through advanced super-resolution optical microscopy. Our groundbreaking optical microscope uniquely integrates spatial and temporal super-resolution for structural and functional imaging in living samples with unprecedented detail. Ourmission is to make high-resolution imaging accessible to all, fostering scientific discovery and advancing healthcare research.

MCF Holding is a holding company of financial investments that engages in the management of events, retail, and real estate business.

Investment focus

Biopharma, Life Science, Biotechnology
Funding Round
Italy

Portfolio highlights

Genoa Instruments — Genoa Instruments is an innovative startup dedicated to transforming the field of biomedical and health research through advanced super-resolution optical microscopy. Our groundbreaking optical microscope uniquely integrates spatial and temporal super-resolution for structural and functional imaging in living samples with unprecedented detail. Ourmission is to make high-resolution imaging accessible to all, fostering scientific discovery and advancing healthcare research.

Deep Blue Ventures is an international holding company that acquires, manages, and scales the next generation of online brands.

Investment focus

Biopharma, Life Science, Biotechnology
Funding Round
Italy

Portfolio highlights

Genoa Instruments — Genoa Instruments is an innovative startup dedicated to transforming the field of biomedical and health research through advanced super-resolution optical microscopy. Our groundbreaking optical microscope uniquely integrates spatial and temporal super-resolution for structural and functional imaging in living samples with unprecedented detail. Ourmission is to make high-resolution imaging accessible to all, fostering scientific discovery and advancing healthcare research.

ReItaly21 is an investment firm.

Investment focus

Biopharma, Life Science, Biotechnology
Funding Round
Italy

Portfolio highlights

Genoa Instruments — Genoa Instruments is an innovative startup dedicated to transforming the field of biomedical and health research through advanced super-resolution optical microscopy. Our groundbreaking optical microscope uniquely integrates spatial and temporal super-resolution for structural and functional imaging in living samples with unprecedented detail. Ourmission is to make high-resolution imaging accessible to all, fostering scientific discovery and advancing healthcare research.

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, France, Italy

Portfolio highlights

vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Cour Pharmaceuticals Development — Reprogramming the immune system. Restoring lives.At COUR, we develop targeted therapies that incite calm within the immune system and help restore the healt ...

Investors by industry